Aspirin plus coumarin vs. aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT)-2 trial

Brouwer, M.A.; Bergh, Paul J.P.C. van den; Aengevaeren, W.R.M.

doi:10.1016/s1062-1458(02)00895-4

Cited by 26 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were similar reductions in the risk of MI/death at 1 year in the diabetic subgroup randomized to an invasive strategy (OR: 0.61; 95% CI: 0.36 to 1.04) compared with patients who did not have diabetes randomized to an invasive strategy (OR: 0.72; 95% CI: 0.54 to 0.95). The risk of death was also reduced by Use of warfarin in conjunction with aspirin and/or P2Y 12 receptor inhibitor therapy is associated with an increased risk of bleeding, and patients and clinicians should watch for bleeding, especially GI, and seek medical evaluation for evidence of bleeding (7,9,13,14,(141)(142)(143)(144) 3. It is reasonable to use an insulin-based regimen to achieve and maintain glucose levels less than 180 mg/dL while avoiding hypoglycemia* for hospitalized patients with UA/NSTEMI with either a complicated or uncomplicated course (149)(150)(151)(152).…”

Section: Intensive Glucose Controlmentioning

confidence: 99%

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

Jneid¹,

Anderson²,

Wright³

et al. 2012

Journal of the American College of Cardiology

502

276

View full text Add to dashboard Cite

Section: Intensive Glucose Controlmentioning

confidence: 99%

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

Jneid¹,

Anderson²,

Wright³

et al. 2012

Journal of the American College of Cardiology

502

276

View full text Add to dashboard Cite

“…Large randomized trials have demonstrated that oral anticoagulants, when given in adequate doses, reduce the rates of adverse outcomes, at the cost of a small increase in hemorrhagic events (1247)(1248)(1249). Large randomized trials have demonstrated that oral anticoagulants, when given in adequate doses, reduce the rates of adverse outcomes, at the cost of a small increase in hemorrhagic events (1247)(1248)(1249).…”

Section: Inhibition Of the Renin-angiotensin-aldosterone Systemmentioning

confidence: 99%

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction

Antman¹,

Anbe²,

Armstrong³

et al. 2004

Journal of the American College of Cardiology

1,008

290

View full text Add to dashboard Cite

The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated and reviewed by the writing committee as changes occur. See Appendix 1 for relationship with industry information for writing committee members; see Appendix 2 for peer reviewer names and relationships with industry for this document.

show abstract

“…13 They demonstrated that in patients recently admitted with acute coronary events, treatment with aspirin combined with medium-intensity oral anticoagulants was more effective than aspirin alone in reduction of subsequent cardiovascular events and death. They also reported that minor bleedings in patients with combination therapy were significantly more numerous than in patients receiving aspirin alone (p < 0.0001), and this latter finding is in accord with our findings about minor bleedings.…”

Section: Discussionmentioning

confidence: 99%

Warfarin and Aspirin Versus Aspirin Alone in Patients with Acute Myocardial Infarction: A Pilot Study

2004

View full text Add to dashboard Cite

The benefits of anticoagulant therapy and antiplatelet agents in secondary prevention of myocardial infarction (MI) are well known. Administration of combined warfarin and aspirin (ASA) has not been well studied. The objective of this study was to compare the effect of coadministration of warfarin and ASA with administration of ASA alone on outcome of patients after MI. One hundred forty age- and sex-matched survivors of MI were randomized to receive either 100 mg/day ASA plus enough warfarin to reach a target: international normalized ratio of 2.5 (range: 2-3) (group A, n = 70), or only 100 mg/day ASA (group B, n = 70). The patients were examined for several variables including development of hemorrhage, reinfarction, and rehospitalization for 1 year post MI. Of the variables studied, minor hemorrhagic episodes were observed significantly (p = 0.002) more in group A than in group B patients. Rehospitalization and reinfarction rates, although occurring with lower frequencies in group A than in group B, did not reach the statistical significance level. In postmyocardial infarction patients, warfarin plus ASA did not provide a clinical benefit beyond that achievable with aspirin monotherapy, and for the observed markedly higher incidence of minor hemorrhage in combination therapy, antiplatelet therapy alone seems to be a more reasonable approach.

show abstract

Aspirin plus coumarin vs. aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT)-2 trial

Cited by 26 publications

References 0 publications

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction

Warfarin and Aspirin Versus Aspirin Alone in Patients with Acute Myocardial Infarction: A Pilot Study

Contact Info

Product

Resources

About